CANCER RESEARCH SERVICES
IMAGING BASED HIGH-THROUGHPUT BIOLOGY FOR CANCER RESEARCH
As general strategy for our cancer research we are aiming to (a) advance use of multi-parameter imaging technologies for patient derived cancer research, (b) use these methods together with genomics studies to interrogate how genomic features in human cancers encode the aberrant molecular, cellular and tissue structures that define the tumors sensitivity to cancer treatments and (c) apply the resulting information to improve therapies and disease management of human cancers.
DIAGNOSTIC THERAPY EFFICACY ASSESSMENT AS A NOVEL PROCEDURE IN RARE CANCER CARE
Precision medicine in cancer care aims to target the treatment of an individual patient on basis of a tailored diagnosis. The advent of genomic big data describing the genetic landscape of human cancers has revived the concept of oncogene defined molecular cancer grouping and resulted in genomic medicine. International efforts providing a pan-cancer comparison of the genomic similarities of tens of thousands of patients now suggest shifting the grouping of cancers towards tissue-agnostic subtypes defined by the genomic aberrations rather than the tissue or cell of origin. This has a profound impact also on the way cancers could be treated as classically cancer treatment strategies have been considered cancer type specific. The hundreds of different forms of cancers originating from different sites of organs and more specifically the different cell types are driven by a complex array of genomic alterations and no two cancers are identical.
HOW TO MATCH PATIENTS WITH THE BEST TREATMENT?
Traditionally cancer classification has been based on histology and pathological evaluation. With advent of the genetic profiling techniques the molecular subtyping has been used to define cancers further down to molecular subtypes. Since the complexity of genomic aberrations and lineage context of tumors result in varying drug sensitivity even within cancer types, further division of molecular tumor subtypes according to drug sensitivity could be based on diagnostic therapy efficacy testing, allowing tissue-agnostic use of cancer drugs.
TRIALTEST™ FOR PREDICTIVE ANALYSIS OF THERAPY EFFICACY IN SOLID CANCERS
We at Misvik Biology are developing a novel platform called TrialTest™ , which is a diagnostic therapy efficacy testing strategy developed in collaborations with health care districts of Finland. TrialTest™ can be used for functional assessment of therapy efficacy in majority of human cancer types. A special feature of the platform is the ability to identify and validate targeted therapeutics for rare cancers. At the moment more than 200 patients representing over 40 different solid cancer types have been tested.